This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Rapid-Acting Insulins and Coformulations:  New Strategies for Safe and Effective Postprandial Glucose Control

Rapid-Acting Insulins and Coformulations: New Strategies for Safe and Effective Postprandial Glucose Control

Format

Webcast

Time to Complete

1.25 hours

Released

May 31, 2019

Expires

May 31, 2020
Add to Queue


Maximum Credits

1.25 / AMA PRA Category 1 CreditsTM
1.25 / CPD Credits

Accredited Provider

Provided by Haymarket Medical Education in collaboration with MIMS and GP MIMS

Commercial Supporter

Supported by an educational grant from Novo Nordisk A/S

Program Description

Poor glycemic control in diabetes is a global problem, despite the availability of numerous glucose-lowering therapies and clear guidelines for patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) management. A failure to intensify treatment in a timely and appropriate manner leads to not only an inability to reach target A1C goals, but also to an increased risk of cardiovascular disease (CVD) morbidity and mortality associated with the disease. Recent studies implicate elevated postprandial glucose (PPG) as an important driver of poor glycemic control.

A disincentive for clinicians to consider intensifying treatment for T2DM patients who require insulin is a fear of inducing hypoglycemia and its attendant complications and impact on patient adherence. This activity is designed to provide insight into a new-generation of rapid-acting insulins and basal insulin coformulations, which have been shown to improve fasting and PPG control and to mitigate the hypoglycemic and CVD effects in a substantial proportion of patients who now are failing to reach optimal A1C targets.

Intended Audience

Endocrinologists, internists, and primary care clinicians (ie, family medicine/family practice physicians, nurse practitioners [NPs], and physician assistants [PAs]) who care for patients with diabetes.

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Recognize and address clinical inertia to ensure timely intensification of treatment as needed in individuals with diabetes
  • Apply an understanding of the prevalence and consequences of hypoglycemia when individualizing treatment plans for patients with diabetes mellitus
  • Assess data on the safety and efficacy of new and emerging insulins and insulin combinations to better inform treatment planning
  • Identify patients who may benefit from rapid-acting insulin to optimize postprandial glucose (PPG) control
  • Conflict Of Interest Disclosure Policy

    In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

    Furthermore, HME seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. HME is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.

    Faculty

    Bruce W. Bode, MD, FACE – Moderator
    Atlanta Diabetes Associates
    Clinical Associate Professor
    Emory University
    Atlanta, GA, USA

    Dr. Bode is a consultant for and receives research grant funds from Insulet Corporation, Medtronic, Novo Nordisk, and Sanofi. Dr. Bode is on the speakers’ bureaus for Insulet Corporation, Lilly, Medtronic, Novo Nordisk, and Sanofi.

    Francesc Xavier Cos Claramunt, MD
    Associate Professor and Chairman
    Primary Care Diabetes Europe
    Universitat Autonoma de Barcelona
    Jordi Gol Institute for Research in Primary Care
    Barcelona, Spain

    Dr. Cos Claramunt is a consultant for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co., Novartis Pharmaceuticals, Roche, Sanofi, and Sanofi Pasteur. His is on the speakers’ bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co., Novartis Pharmaceuticals, Merck Sharp & Dohme Corp., Roche, Sanofi, and Sanofi Pasteur. Dr. Cos Claramunt receives research grant funds from AstraZeneca and Novartis Pharmaceuticals.

    Stefano Del Prato, MD
    Professor of Endocrinology
    Chief, Section of Diabetes and Metabolic Diseases
    Department of Clinical and Experimental Medicine
    University of Pisa
    Pisa, Italy

    Dr. Del Prato is a consultant for Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co., GlaxoSmithKline, Laboratoires Servier, Merck & Co., Inc., Novartis Pharmaceuticals, Novo Nordisk, Sanofi, and Takeda Pharmaceuticals. He receives research grant funds from AstraZeneca, Boehringer Ingelheim, Merck & Co., Inc., and Novartis Pharmaceuticals.

    Kamlesh Khunti, MD, PhD, FRCP, FRCGP, FMedSci
    Professor and Head, Primary Care Diabetes and Vascular Medicine Department
    Diabetes Research Centre
    University of Leicester
    Leicester, UK

    Dr. Khunti is a consultant for Amgen, AstraZeneca, Bayer, Berlin-Chemie AG/Menarini Group, Eli Lilly and Co., Merck Sharp & Dohme Corp., NAPP Pharmaceuticals Ltd., Novartis Pharmaceuticals, Novo Nordisk, Roche, Sanofi-Aventis, and Laboratoires Servier. He is on the speakers’ bureaus for AstraZeneca, Bayer, Berlin-Chemie AG/Menarini Group, Eli Lilly and Co., Merck Sharp & Dohme Corp., NAPP Pharmaceuticals Ltd., Novartis Pharmaceuticals, Novo Nordisk, Roche, and Sanofi-Aventis. Dr. Khunti receives research grant funds and is on the advisory boards for Eli Lilly and Co., Novo Nordisk, and Sanofi-Aventis.

    Andreas Liebl, MD
    Medical Director, Department for Internal Medicine
    Center for Diabetes and Metabolism
    Fachklinik Bad Heilbrunn
    Bad Heilbrunn, Germany

    Dr. Liebl is on the speakers’ bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co., Medtronic, Merck Sharp & Dohme Corp., Novo Nordisk, Roche, and Sanofi. Dr. Liebl is a consultant for Becton Dickinson, Boehringer Ingelheim, Eli Lilly and Co., Merck Sharp & Dohme Corp., Novo Nordisk, and Roche.

    Yves Reznik, MD
    University Professor, Hospital Practitioner
    Head, Department of Diabetes and Endocrinology
    CHU Côte de Nacre
    Caen, France

    Dr. Reznik has no relevant financial relationships to disclose.

    Accredited Provider Disclosure

    Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.

    Credit

    1.25

    Type

    AMA PRA Category 1 Credit(s)TM

    Accreditation Statement

    Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Designation Statement

    Haymarket Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Additional Credit Information

    CPD credit information for UK healthcare professionals
    This activity has been produced by the Haymarket Medical Education editorial team, under the guidance of the MIMS Learning expert faculty. A recommended learning credit value of 1.25 CPD credits (1 hour 15 minutes of learning activity) is provided to assist the participant.

    This credit value is in line with the recommendations of the Royal College of General Practitioners.

    Physician Assistant Continuing Education
    AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM  from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 Credit for completing this activity.

    Nurse Practitioner Continuing Education
    The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM  from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

    This activity is awarded 1.00 contact hour.

    Disclosure of Unlabeled Use

    This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet approved by the European Medicine Agency (EMA). Participants should note that the use of products outside currently EMA-approved labeling should be considered experimental and are advised to consult current prescribing information for EMA-approved indications.

    Faculty, speakers, presenters, authors, activity medical directors, and moderators are required to disclose to the learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not EMA-approved) as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

    Disclaimer

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Novo Nordisk A/S. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    If you have any questions relating to the CME accreditation of this activity, please contact HME at cmequestions@haymarketmedical.com.

    If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

    Instructions

    To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

    SYSTEM REQUIREMENTS

    Hardware and Software Requirements
    • A computer with an internet connection
    • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
    • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
    Add to Queue